

Cancer Drug Pipeline Information for Patient Advocacy Groups

Please note: CCAN and CADTH do not represent or warrant that any of the drug products listed in the Cancer Drug Pipeline Information for Patient Advocacy Groups will be submitted to the pCODR program. The use of this information is solely intended for informational purposes to assist patient advocacy groups to be more informed about the anticipated cancer drug products or indications that are listed in the pipeline. Please be advised that the information contained in this document is not a comprehensive list. Please contact info@canceraction.ca with any inquiries about the information contained in this document.

Brand Name	Generic Name	Manufacturer	Indication	Route of Administration	Information Source
Breast Cancer					
	abemaciclib	Eli Lilly	Postmenopausal women with hormone-receptor-positive, HER2-negative locoregionally recurrent or metastatic breast cancer	Oral	http://lillyoncologypipeline.com/molecule/cdk-4-and-cdk-6-inhibitor/trials
	abemaciclib	Eli Lilly	with Trastuzumab in Women With Hormone-Receptor-Positive, HER2-Positive Locally Advanced or Metastatic Breast Cancer	Oral	http://lillyoncologypipeline.com/molecule/cdk-4-and-cdk-6-inhibitor/trials
	alpelisib	Novartis	Advanced Breast Cancer That Has Progressed on or After Treatment With an Aromatase Inhibitor	Oral	http://www.trials.novartis.com/en/clinical-trials/us-oncology/oncology/solar/solar-1/overview/
Tecentriq	atezolizumab	Hoffmann-La Roche	Metastatic triple-negative breast cancer, first-line treatment	Intravenous	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm
	AZD5363	AstraZeneca	Breast cancer		https://www.astrazeneca.com/our-focus-areas/oncology.html
Avastin	bevacizumab	Genentech	Adjuvant breast cancer, HER2-negative	Intravenous	http://www.gene.com/medical-professionals/pipeline
Avastin	bevacizumab	Genentech	Adjuvant breast cancer, HER2-positive	Intravenous	http://www.gene.com/medical-professionals/pipeline
	buparlisib	Novartis	Breast cancer Phase 2	Oral	https://www.novartisoncology.com/about-us/our-pipeline
Cometriq	cabozantinib	Exelixis	Breast cancer: patients with brain metastases	Oral	http://www.exelixis.com/sites/default/files/pdf/Cabozantinib%20Clinical%20Trials%20-%20November%202016.pdf

Cancer Drug Pipeline Information for Patient Advocacy Groups

Please note: CCAN and CADTH do not represent or warrant that any of the drug products listed in the Cancer Drug Pipeline Information for Patient Advocacy Groups will be submitted to the pCODR program. The use of this information is solely intended for informational purposes to assist patient advocacy groups to be more informed about the anticipated cancer drug products or indications that are listed in the pipeline. Please be advised that the information contained in this document is not a comprehensive list. Please contact info@canceraction.ca with any inquiries about the information contained in this document.

Brand Name	Generic Name	Manufacturer	Indication	Route of Administration	Information Source
Cometriq	cabozantinib	Exelixis	Breast cancer: metastatic, hormone-receptor positive	Oral	http://www.exelixis.com/sites/default/files/pdf/Cabozantinib%20Clinical%20Trials%20-%20November%202016.pdf
Cotellic	cobimetinib	Hoffmann-La Roche	First line metastatic triple negative breast cancer	Oral	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm
Xgeva	denosumab	Amgen	Delay or prevention of bone metastases in patients with adjuvant breast cancer	Subcutaneous	http://www.amgenpipeline.com/pipeline/
Xtandi	enzalutamide	Astellas Pharma	Breast cancer (ER/PgR positive, HER2 positive)	Oral	https://www.astellas.com/en/ir/library/pdf/2q2017_rd_en.pdf
Xtandi	enzalutamide	Astellas Pharma	Triple-negative breast cancer	Oral	https://www.astellas.com/en/ir/library/pdf/2q2017_rd_en.pdf
Halaven	eribulin	Eisai	Breast cancer	Intravenous	http://www.eisai.com/pdf/eir/erepo/epipeline.pdf
	ipatasertib	Genentech	Triple-negative breast cancer	Oral	http://www.gene.com/medical-professionals/pipeline
	ipatasertib	Hoffmann-La Roche	Triple-negative breast cancer, adjuvant treatment	Oral	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm
	ipatasertib	Hoffmann-La Roche	Triple-negative breast cancer, first-line treatment	Oral	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm
	MEDI-573	AstraZeneca	Metastatic breast cancer		https://www.astrazeneca.com/our-focus-areas/oncology.html
	neratinib	Puma	Metastatic HER2 non-amplified but HER2 mutant breast cancer, alone and in combination with fulvestrant	Oral	https://clinicaltrials.gov/show/NCT01670877
	oral azacitidine (CC-486)	Celgene	Metastatic breast cancer	Oral	https://www.celgene.com/content/uploads/product-pipeline.pdf
Abraxane	nab-paclitaxel	Celgene	First-line metastatic triple-negative breast cancer	Intravenous	https://www.celgene.com/content/uploads/product-pipeline.pdf

Cancer Drug Pipeline Information for Patient Advocacy Groups

Please note: CCAN and CADTH do not represent or warrant that any of the drug products listed in the Cancer Drug Pipeline Information for Patient Advocacy Groups will be submitted to the pCODR program. The use of this information is solely intended for informational purposes to assist patient advocacy groups to be more informed about the anticipated cancer drug products or indications that are listed in the pipeline. Please be advised that the information contained in this document is not a comprehensive list. Please contact info@canceraction.ca with any inquiries about the information contained in this document.

Brand Name	Generic Name	Manufacturer	Indication	Route of Administration	Information Source
Ibrance	palbociclib	Pfizer	Recurrent advanced breast cancer	Oral	http://www.pfizer.com/sites/default/files/product-pipeline/PfizerPipeline_1.pdf
Ibrance	palbociclib	Pfizer	High-risk early breast cancer	Oral	http://www.pfizer.com/sites/default/files/product-pipeline/PfizerPipeline_1.pdf
Ibrance	palbociclib	Pfizer	Early breast cancer in adjuvant setting	Oral	http://www.pfizer.com/sites/default/files/product-pipeline/PfizerPipeline_1.pdf
Ibrance	palbociclib	Pfizer	For the treatment of women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer with disease progression following endocrine therapy in combination with fulvestrant	Oral	http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm487080.htm
Ibrance	palbociclib	Pfizer	Recurrent advanced breast cancer	Oral	http://www.pfizer.com/sites/default/files/product-pipeline/Produce_Pipeline_Update.pdf
Keytruda	pembrolizumab	Merck	Breast cancer	Intravenous	http://www.merck.com/research/pipeline/home.html
Perjeta	pertuzumab	Genentech	Early HER2-positive breast cancer	Intravenous	http://www.gene.com/medical-professionals/pipeline
Perjeta	pertuzumab	Genentech	2nd line HER2-negative breast cancer	Intravenous	http://www.gene.com/medical-professionals/pipeline
Perjeta	pertuzumab	Hoffmann-La Roche	Early HER2-positive breast cancer	Intravenous	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm
	ribociclib	Novartis	For the treatment of postmenopausal women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer	Oral	https://www.novartis oncology.com/about-us/our-pipeline

Cancer Drug Pipeline Information for Patient Advocacy Groups

Please note: CCAN and CADTH do not represent or warrant that any of the drug products listed in the Cancer Drug Pipeline Information for Patient Advocacy Groups will be submitted to the pCODR program. The use of this information is solely intended for informational purposes to assist patient advocacy groups to be more informed about the anticipated cancer drug products or indications that are listed in the pipeline. Please be advised that the information contained in this document is not a comprehensive list. Please contact info@canceraction.ca with any inquiries about the information contained in this document.

Brand Name	Generic Name	Manufacturer	Indication	Route of Administration	Information Source
	ribociclib	Novartis	Breast cancer	Oral	https://www.novartis oncology.com/about-us/our-pipeline
	SERD (GDC-0810)	Genentech	ER+ HER2-negative breast cancer	Oral	http://www.gene.com/medical-professionals/pipeline
	TAK-228	Takeda	Breast cancer	Oral	https://www.takeda oncology.com/content/assets/Takeda-Global-Oncology-Pipeline.pdf
	talazoparib	Pfizer	Germline BRCA-mutated metastatic breast cancer	Oral	http://www.pfizer.com/sites/default/files/product-pipeline/PfizerPipeline_1.pdf
	taselisib	Hoffmann-La Roche	HER2-negative, hormone receptor-positive metastatic breast cancer, neoadjuvant treatment	Oral	http://www.roche.com/research_and_development/who_we_are/how_we_work/pipeline.htm
Kadcyla	trastuzumab emtansine	Genentech	1st line HER2-positive metastatic breast cancer	Intravenous	http://www.gene.com/medical-professionals/pipeline
Kadcyla	trastuzumab emtansine	Hoffmann-La Roche	Early HER2-positive breast cancer, adjuvant treatment, in combination with Perjeta	Intravenous	http://www.roche.com/research_and_development/who_we_are/how_we_work/pipeline.htm
Kadcyla	trastuzumab emtansine	Hoffmann-La Roche	Second line HER2-positive metastatic breast cancer, in combination with Tecentriq	Intravenous	http://www.roche.com/research_and_development/who_we_are/how_we_work/pipeline.htm
Kadcyla	trastuzumab emtansine	Hoffmann-La Roche	Third-line HER2-positive metastatic breast cancer	Intravenous	http://www.roche.com/research_and_development/who_we_are/how_we_work/pipeline.htm
	veliparib	AbbVie	BRCA breast cancer	Oral	http://www.abbvie.com/research-innovation/pipeline.html
	veliparib	AbbVie	Neoadjuvant treatment of triple negative breast cancer	Oral	http://www.abbvie.com/research-innovation/pipeline.html
	xentuzumab	Boehringer Ingelheim	Metastatic breast cancer (oestrogen-receptor positive)		http://www.inoncology.com/trials/phase11.html

Cancer Drug Pipeline Information for Patient Advocacy Groups

Please note: CCAN and CADTH do not represent or warrant that any of the drug products listed in the Cancer Drug Pipeline Information for Patient Advocacy Groups will be submitted to the pCODR program. The use of this information is solely intended for informational purposes to assist patient advocacy groups to be more informed about the anticipated cancer drug products or indications that are listed in the pipeline. Please be advised that the information contained in this document is not a comprehensive list. Please contact info@canceraction.ca with any inquiries about the information contained in this document.

Brand Name	Generic Name	Manufacturer	Indication	Route of Administration	Information Source
Endocrine Cancer					
Avastin	bevacizumab	Genentech	High-risk carcinoid	Intravenous	http://www.gene.com/medical-professionals/pipeline
Cometriq	cabozantinib	Exelixis	Medullary thyroid cancer	Oral	http://www.exelixis.com/sites/default/files/pdf/Cabozantinib%20Clinical%20Trials%20-%20November%202016.pdf
Cometriq	cabozantinib	Exelixis	Differentiated thyroid cancer	Oral	http://www.exelixis.com/sites/default/files/pdf/Cabozantinib%20Clinical%20Trials%20-%20November%202016.pdf
	selumetinib	AstraZeneca	Differentiated thyroid cancer	Oral	https://www.astrazeneca.com/our-focus-areas/oncology.html
Zelboraf	vemurafenib	Genentech	Papillary thyroid cancer, BRAF mutation positive	Oral	http://www.gene.com/medical-professionals/pipeline

Cancer Drug Pipeline Information for Patient Advocacy Groups

Please note: CCAN and CADTH do not represent or warrant that any of the drug products listed in the Cancer Drug Pipeline Information for Patient Advocacy Groups will be submitted to the pCODR program. The use of this information is solely intended for informational purposes to assist patient advocacy groups to be more informed about the anticipated cancer drug products or indications that are listed in the pipeline. Please be advised that the information contained in this document is not a comprehensive list. Please contact info@canceraction.ca with any inquiries about the information contained in this document.

Brand Name	Generic Name	Manufacturer	Indication	Route of Administration	Information Source
Gastrointestinal Cancer					
	abemaciclib	Eli Lilly	Pancreatic cancer	Oral	http://lillyoncologypipeline.com/molecule/cdk-4-and-cdk-6-inhibitor/trials
	Andecaliximab	Gilead Sciences	Gastric Cancer	Subcutaneous	http://www.gilead.com/research/pipeline
	avelumab	EMD Serono	First line gastric cancer	Intravenous	http://www.emdserono.com/en/research/Pipeline/research.html
	avelumab	EMD Serono	Third line gastric cancer	Intravenous	http://www.emdserono.com/en/research/Pipeline/research.html
	AZD6738	AstraZeneca	Gastric cancer, in combination with lynparza		https://www.astrazeneca.com/our-focus-areas/oncology.html
	binimetinib	Array BioPharma	BRAF-mutant colorectal cancer in combination with encorafenib and cetuximab	Oral	http://www.arraybiopharma.com/product-pipeline/binimetinib/
	buparlisib	Novartis	Gastroesophageal junction cancer	Oral	https://www.novartis oncology.com/about-us/our-pipeline
Cometriq	cabozantinib	Exelixis	Advanced hepatocellular cancer	Oral	http://www.exelixis.com/pipeline
Cotellic	cobimetinib	Hoffmann-La Roche	Third-line advanced or metastatic colorectal cancer, in combination with Tecentriq	Oral	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm
	codrituzumab	Hoffmann-La Roche	Metastatic liver cancer		http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm
	durvalumab + tremelimumab	AstraZeneca	Gastric cancer	Intravenous	https://www.astrazeneca.com/our-focus-areas/oncology.html
	durvalumab + tremelimumab	AstraZeneca	Metastatic pancreatic ductal carcinoma	Intravenous	https://www.astrazeneca.com/our-focus-areas/oncology.html
	durvalumab + tremelimumab	AstraZeneca	Hepatocellular carcinoma	Intravenous	https://www.astrazeneca.com/our-science/pipeline.html

Cancer Drug Pipeline Information for Patient Advocacy Groups

Please note: CCAN and CADTH do not represent or warrant that any of the drug products listed in the Cancer Drug Pipeline Information for Patient Advocacy Groups will be submitted to the pCODR program. The use of this information is solely intended for informational purposes to assist patient advocacy groups to be more informed about the anticipated cancer drug products or indications that are listed in the pipeline. Please be advised that the information contained in this document is not a comprehensive list. Please contact info@canceraction.ca with any inquiries about the information contained in this document.

Brand Name	Generic Name	Manufacturer	Indication	Route of Administration	Information Source
	encorafenib	Array BioPharma	BRAF-mutant colorectal cancer in combination with binimetinib and cetuximab	Oral	http://www.arraybiopharma.com/product-pipeline/encorafenib-lgx818/
Xtandi	enzalutamide	Astellas Pharma	Hepatocellular carcinoma	Oral	https://www.astellas.com/en/ir/library/pdf/2q2017_rd_en.pdf
	galunisertib	Eli Lilly	Hepatocellular Carcinoma	Oral	http://lillyoncologypipeline.com/molecule/tgf-beta-r-1-kinase-inhibitor/trials
	ipatasertib	Genentech	Gastric cancer	Oral	http://www.gene.com/medical-professionals/pipeline
Imbruvica	ibrutinib	AbbVie	Pancreatic cancer	Oral	https://www.abbvie.com/our-science/pipeline.html
Somatuline	lanreotide	Ipsen Pharma	Unresectable, well or moderately differentiated, locally, advanced or metastatic gastroenteropancreatic neuroendocrine tumors	Subcutaneous	http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm427065.htm
Lenvima	lenvatinib	Eisai	Hepatocellular carcinoma	Oral	http://www.eisai.com/pdf/eir/erepo/epipeline.pdf
Lenvima	lenvatinib	Eisai	Biliary tract cancer	Oral	http://www.eisai.com/pdf/eir/erepo/epipeline.pdf
Masivet	masitinib	AB Science	Relapsed metastatic colorectal cancer	Oral	http://www.ab-science.com/en/human-medicine/masitinib-in-oncology
Masivet	masitinib	AB Science	Metastatic pancreatic cancer	Oral	http://www.ab-science.com/en/human-medicine/masitinib-in-oncology
Masivet	masitinib	AB Science	Gastrointestinal stromal tumour, first-line treatment	Oral	http://www.ab-science.com/en/human-medicine/masitinib-in-oncology
Masivet	masitinib	AB Science	Gastrointestinal stromal tumour, second-line treatment	Oral	http://www.ab-science.com/en/human-medicine/masitinib-in-oncology
	merestinib	Eli Lilly	First-line advanced or metastatic biliary tract cancer	Oral	http://lillyoncologypipeline.com/molecule/met-inhibitor/trials
Abraxane	nab-paclitaxel	Celgene	Adjuvant therapy for pancreatic cancer	Intravenous	https://www.celgene.com/content/uploads/product-pipeline.pdf

Cancer Drug Pipeline Information for Patient Advocacy Groups

Please note: CCAN and CADTH do not represent or warrant that any of the drug products listed in the Cancer Drug Pipeline Information for Patient Advocacy Groups will be submitted to the pCODR program. The use of this information is solely intended for informational purposes to assist patient advocacy groups to be more informed about the anticipated cancer drug products or indications that are listed in the pipeline. Please be advised that the information contained in this document is not a comprehensive list. Please contact info@canceraction.ca with any inquiries about the information contained in this document.

Brand Name	Generic Name	Manufacturer	Indication	Route of Administration	Information Source
Vectibix	panitumumab	Amgen	Chemorefractory, wild-type KRAS exon 2 metastatic colorectal cancer	Intravenous	http://www.amgenpipeline.com/pipeline/
Keytruda	pembrolizumab	Merck	Esophageal cancer	Intravenous	http://www.merck.com/research/pipeline/home.html
Keytruda	pembrolizumab	Merck	Gastric cancer	Intravenous	http://www.merck.com/research/pipeline/home.html
Keytruda	pembrolizumab	Merck	Colorectal Cancer	Intravenous	http://www.merck.com/research/pipeline/home.html
Keytruda	pembrolizumab	Merck	Liver cancer	Intravenous	http://www.merck.com/research/pipeline/MerckPipeline.pdf
Perjeta	pertuzumab	Hoffmann-La Roche	Advanced HER2-positive gastric cancer	Intravenous	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm
Cyamza	ramucirumab	Eli Lilly	Metastatic colorectal cancer, in combination with Folfiri, for patients whose disease has progressed on a first line bevacizumab, oxaliplatin, and fluoropyrimidine-containing regimen	Intravenous	http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm444496.htm
Cyamza	ramucirumab	Eli Lilly	Gastric cancer - Phase 3	Intravenous	http://lillyoncologypipeline.com/clinical-phase/III
Cyamza	ramucirumab	Eli Lilly	Second-line treatment in patients with hepatocellular carcinoma and elevated Baseline alpha-fetoprotein (AFP) following first-line therapy with sorafenib	Intravenous	http://lillyoncologypipeline.com/molecule/vegfr-receptor-2-antagonist/trials
Cyamza	ramucirumab	Eli Lilly	Second-line metastatic or locally advanced, unresectable gastric or gastroesophageal junction adenocarcinoma, in combination with paclitaxel	Intravenous	http://lillyoncologypipeline.com/molecule/vegfr-receptor-2-antagonist/trials

Cancer Drug Pipeline Information for Patient Advocacy Groups

Please note: CCAN and CADTH do not represent or warrant that any of the drug products listed in the Cancer Drug Pipeline Information for Patient Advocacy Groups will be submitted to the pCODR program. The use of this information is solely intended for informational purposes to assist patient advocacy groups to be more informed about the anticipated cancer drug products or indications that are listed in the pipeline. Please be advised that the information contained in this document is not a comprehensive list. Please contact info@canceraction.ca with any inquiries about the information contained in this document.

Brand Name	Generic Name	Manufacturer	Indication	Route of Administration	Information Source
Cyramza	ramucirumab	Eli Lilly	Advanced gastric or gastroesophageal junction adenocarcinoma, refractory to or progressive after first-line therapy with platinum and fluoropyrimidine	Intravenous	http://lillyoncologypipeline.com/molecule/vegfr-receptor-2-antagonist/trials
	ramucirumab	Eli Lilly	Metastatic gastric or gastroesophageal junction adenocarcinoma	Intravenous	http://lillyoncologypipeline.com/molecule/vegfr-receptor-2-antagonist/trials
Stivarga	regorafenib	Bayer	Hepatocellular carcinoma (HCC) 2nd line	Oral	http://pharma.bayer.com/en/innovation-partnering/development-pipeline/
Stivarga	regorafenib	Bayer	3rd-line or beyond treatment for gastrointestinal stromal tumours	Oral	http://pharma.bayer.com/en/innovation-partnering/clinical-trials/trial-finder/
Stivarga	regorafenib	Bayer	Patients with gastrointestinal tumours who have progressed after standard therapy	Oral	http://pharma.bayer.com/en/innovation-partnering/clinical-trials/trial-finder/
Stivarga	regorafenib	Bayer	Patients with metastatic colorectal cancer who have progressed after standard therapy	Oral	http://pharma.bayer.com/en/innovation-partnering/clinical-trials/trial-finder/
Stivarga	regorafenib	Bayer	Asian patients with metastatic colorectal cancer after failure of standard therapy	Oral	http://pharma.bayer.com/en/innovation-partnering/clinical-trials/trial-finder/
Stivarga	regorafenib	Bayer	Metastatic colorectal cancer after failure of standard therapy	Oral	http://pharma.bayer.com/en/innovation-partnering/clinical-trials/trial-finder/
Stivarga	regorafenib	Bayer	Hepatocellular carcinoma	Oral	http://pharma.bayer.com/en/innovation-partnering/clinical-trials/trial-finder/
Stivarga	regorafenib	Bayer	First-line treatment of metastatic colorectal cancer with mFOLFOX6 in combination with regorafenib	Oral	http://pharma.bayer.com/en/innovation-partnering/clinical-trials/trial-finder/

Cancer Drug Pipeline Information for Patient Advocacy Groups

Please note: CCAN and CADTH do not represent or warrant that any of the drug products listed in the Cancer Drug Pipeline Information for Patient Advocacy Groups will be submitted to the pCODR program. The use of this information is solely intended for informational purposes to assist patient advocacy groups to be more informed about the anticipated cancer drug products or indications that are listed in the pipeline. Please be advised that the information contained in this document is not a comprehensive list. Please contact info@canceraction.ca with any inquiries about the information contained in this document.

Brand Name	Generic Name	Manufacturer	Indication	Route of Administration	Information Source
Stivarga	regorafenib	Bayer	For the treatment of patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib.	Oral	https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm555930.htm
	tepotinib	EMD Serono	Hepatocellular cancer	Oral	http://www.emdserono.com/en/research/Pipeline/research.html Added
	vanucizumab	Hoffmann-La Roche	Colorectal cancer		http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm

Cancer Drug Pipeline Information for Patient Advocacy Groups

Please note: CCAN and CADTH do not represent or warrant that any of the drug products listed in the Cancer Drug Pipeline Information for Patient Advocacy Groups will be submitted to the pCODR program. The use of this information is solely intended for informational purposes to assist patient advocacy groups to be more informed about the anticipated cancer drug products or indications that are listed in the pipeline. Please be advised that the information contained in this document is not a comprehensive list. Please contact info@canceraction.ca with any inquiries about the information contained in this document.

Brand Name	Generic Name	Manufacturer	Indication	Route of Administration	Information Source
Genitourinary Cancer					
Zytiga	abiraterone acetate	Janssen	Prostate Cancer Newly Diagnosed Hormone Naïve Metastatic	Oral	http://files.shareholder.com/downloads/JNJ/200945477x0x674691/1423ebb6-9534-413e-9af6-c0b1c429da15/JNJ_Pipeline.pdf
	apalutamide	Janssen	Pre-metastatic, castration-resistant prostate cancer	Oral	http://files.shareholder.com/downloads/JNJ/2464592300x0x674691/1423ebb6-9534-413e-9af6-c0b1c429da15/JNJ_Pipeline.pdf
	apalutamide	Janssen	Metastatic hormone-sensitive prostate cancer	Oral	http://files.shareholder.com/downloads/JNJ/2464592300x0x674691/1423ebb6-9534-413e-9af6-c0b1c429da15/JNJ_Pipeline.pdf
	apalutamide	Janssen	Localized prostate cancer	oral	http://files.shareholder.com/downloads/JNJ/2464592300x0x674691/1423ebb6-9534-413e-9af6-c0b1c429da15/JNJ_Pipeline.pdf
	apalutamide	Janssen	Metastatic castration-resistant chemotherapy-naïve prostate cancer, in combination with abiraterone acetate	oral	http://files.shareholder.com/downloads/JNJ/200945477x0x674691/1423ebb6-9534-413e-9af6-c0b1c429da15/JNJ_Pipeline.pdf
	ASG-16C3F	Astellas Pharma	Renal cell carcinoma	Injection	https://www.astellas.com/en/ir/library/medical.html
Tecentriq	atezolizumab	Genentech	For locally advanced or metastatic urothelial carcinoma who have disease progression during or following platinum-containing chem or have disease progression within 12 mo's of neoadjuvant or adjuvant treatment with platinum-containing chemo	Intravenous	http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm501878.htm
Tecentriq	atezolizumab	Hoffmann-La Roche	Second-line urothelial bladder cancer	Intravenous	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm

Cancer Drug Pipeline Information for Patient Advocacy Groups

Please note: CCAN and CADTH do not represent or warrant that any of the drug products listed in the Cancer Drug Pipeline Information for Patient Advocacy Groups will be submitted to the pCODR program. The use of this information is solely intended for informational purposes to assist patient advocacy groups to be more informed about the anticipated cancer drug products or indications that are listed in the pipeline. Please be advised that the information contained in this document is not a comprehensive list. Please contact info@canceraction.ca with any inquiries about the information contained in this document.

Brand Name	Generic Name	Manufacturer	Indication	Route of Administration	Information Source
Tecentriq	atezolizumab	Hoffmann-La Roche	1st-line cis-ineligible and 2nd-line metastatic urothelial bladder cancer	Intravenous	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm
Tecentriq	atezolizumab	Hoffmann-La Roche	Renal cell cancer, in combination with Avastin	Intravenous	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm
Tecentriq	atezolizumab	Hoffmann-La Roche	Muscle-invasive bladder cancer, adjuvant treatment	Intravenous	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm
Tecentriq	atezolizumab	Hoffmann-La Roche	First-line cisplatin-ineligible metastatic urothelial carcinoma	Intravenous	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm
Tecentriq	atezolizumab	Hoffmann-La Roche	Renal cell carcinoma, adjuvant treatment	Intravenous	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm
Tecentriq	atezolizumab	Hoffmann-La Roche	Castration-resistant prostate cancer	Intravenous	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm
	avelumab	EMD Serono	First line renal cell carcinoma	Intravenous	http://www.emdserono.com/en/research/Pipeline/research.html
	avelumab	EMD Serono	Urothelial cancer 1L1	Intravenous	http://www.emdserono.com/en/research/Pipeline/research.html
	avelumab	EMD Serono	Urothelial cancer 1L2	Intravenous	http://www.emdserono.com/en/research/Pipeline/research.html
Bavencio	avelumab	EMD Serono	For patients with locally advanced or metastatic urothelial carcinoma whose disease progressed during or following platinum-containing chemotherapy or within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy.	Intravenous	https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm555930.htm
	avelumab	Pfizer	First line urothelial cancer	Intravenous	http://www.pfizer.com/sites/default/files/product-pipeline/PfizerPipeline_1.pdf
	avelumab	Pfizer	1st Line Renal Cell Carcinoma (Biologic) (Combo w/ Inlyta (axitinib))		http://www.pfizer.com/sites/default/files/product-pipeline/013117-Pipeline-Update.pdf

Cancer Drug Pipeline Information for Patient Advocacy Groups

Please note: CCAN and CADTH do not represent or warrant that any of the drug products listed in the Cancer Drug Pipeline Information for Patient Advocacy Groups will be submitted to the pCODR program. The use of this information is solely intended for informational purposes to assist patient advocacy groups to be more informed about the anticipated cancer drug products or indications that are listed in the pipeline. Please be advised that the information contained in this document is not a comprehensive list. Please contact info@canceraction.ca with any inquiries about the information contained in this document.

Brand Name	Generic Name	Manufacturer	Indication	Route of Administration	Information Source
Inlyta	axitinib	Pfizer	Renal cell carcinoma adjuvant, in combination with pembrolizumab	Oral	http://www.pfizer.com/sites/default/files/product-pipeline/PfizerPipeline_1.pdf
Cometriq	cabozantinib	Exelixis	Metastatic renal cell cancer	Oral	http://www.exelixis.com/pipeline
Cometriq	cabozantinib	Exelixis	For treatment of advanced renal cell carcinoma following one prior anti-angiogenic therapy	Oral	http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm501878.htm
Cometriq	cabozantinib	Exelixis	Advanced renal cell carcinoma: previously untreated intermediate or poor-risk patients	Oral	http://www.exelixis.com/sites/default/files/pdf/Cabozantinib%20Clinical%20Trials%20-%20November%202016.pdf
	durvalumab	AstraZeneca	Advanced bladder cancer	Intravenous	https://www.astrazeneca.com/our-focus-areas/oncology.html
Imfinzi	Durvalumab	AstraZeneca	Treatment of locally advanced or metastatic urothelial carcinoma who have disease progression during or following platinum-containing chemo or who have disease progression within 12 mo. of neoadjuvant or adjuvant treatment with platinum-containing chemo		https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm555930.htm
	durvalumab + tremelimumab	AstraZeneca	1st-line bladder cancer	Intravenous	https://www.astrazeneca.com/our-focus-areas/oncology.html
	enfortumab vedotin	Astellas Pharma	Urothelial cancer	Injection	https://www.astellas.com/en/ir/library/medical.html
Xtandi	enzalutamide	Astellas Pharma	Non-metastatic castration-resistant prostate cancer	Oral	https://www.astellas.com/en/ir/library/pdf/2q2017_rd_en.pdf
Xtandi	enzalutamide	Astellas Pharma	Metastatic hormone-sensitive prostate cancer	Oral	https://www.astellas.com/en/ir/library/pdf/2q2017_rd_en.pdf
Xtandi	enzalutamide	Astellas Pharma	Prostate cancer in patients with non-metastatic biochemical recurrence	Oral	https://www.astellas.com/en/ir/library/pdf/2q2017_rd_en.pdf

Cancer Drug Pipeline Information for Patient Advocacy Groups

Please note: CCAN and CADTH do not represent or warrant that any of the drug products listed in the Cancer Drug Pipeline Information for Patient Advocacy Groups will be submitted to the pCODR program. The use of this information is solely intended for informational purposes to assist patient advocacy groups to be more informed about the anticipated cancer drug products or indications that are listed in the pipeline. Please be advised that the information contained in this document is not a comprehensive list. Please contact info@canceraction.ca with any inquiries about the information contained in this document.

Brand Name	Generic Name	Manufacturer	Indication	Route of Administration	Information Source
	erdafitinib	Janssen	Urothelial cancer	Oral	http://files.shareholder.com/downloads/JNJ/1513548902x0x674691/1423ebb6-9534-413e-9af6-c0b1c429da15/JNJ_Pipeline.pdf
Halaven	eribulin	Astellas Pharma	For the treatment of patients with unresectable or metastatic liposarcoma who have received a prior anthracycline-containing regimen.	Intravenous	http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm279174.htm
	ipatasertib	Hoffmann-La Roche	Castration-resistant prostate cancer	Oral	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm
Lenvima	lenvatinib	Eisai	First-line renal cell carcinoma	Oral	http://www.eisai.com/pdf/eir/erepo/epipeline.pdf
Lenvima	lenvatinib	Eisai	For treatment of advanced renal cell carcinoma following one prior anti-angiogenic therapy, , in combination with everolimus	Oral	http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm501878.htm
	LY3023414	Eli Lilly	Prostate cancer	Oral	http://lillyoncologypipeline.com/clinical-phase/II
Masivet	masitinib	AB Science	Metastatic Castrate Resistant Prostate Cancer in first line - treatment of patients with metastatic Castrate Resistant Prostate Cancer in first line	Oral	Metastatic Castrate Resistant Prostate Cancer in first line - treatment of patients with metastatic Castrate Resistant Prostate Cancer in first line
	niraparib	Janssen	Metastatic castrate resistant prostate cancer	Oral	http://files.shareholder.com/downloads/JNJ/1513548902x0x674691/1423ebb6-9534-413e-9af6-c0b1c429da15/JNJ_Pipeline.pdf

Cancer Drug Pipeline Information for Patient Advocacy Groups

Please note: CCAN and CADTH do not represent or warrant that any of the drug products listed in the Cancer Drug Pipeline Information for Patient Advocacy Groups will be submitted to the pCODR program. The use of this information is solely intended for informational purposes to assist patient advocacy groups to be more informed about the anticipated cancer drug products or indications that are listed in the pipeline. Please be advised that the information contained in this document is not a comprehensive list. Please contact info@canceraction.ca with any inquiries about the information contained in this document.

Brand Name	Generic Name	Manufacturer	Indication	Route of Administration	Information Source
Opdivo	nivolumab	Bristol-Myers Squibb	Locally advanced or metastatic urothelial carcinoma who have disease progression during or following platinum-containing chemotherapy or have disease progression within 12 months of neoadjuvant or adjuvant treatment with a platinum-containing chemotherapy	Intravenous	https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm539646.htm
Keytruda	pembrolizumab	Merck	Bladder cancer	Intravenous	http://www.merck.com/research/pipeline/home.html
Keytruda	pembrolizumab	Merck	Prostate cancer	Intravenous	http://www.merck.com/research/pipeline/MerckPipeline.pdf
Cyramza	ramucirumab	Eli Lilly	Patients with locally advanced or unresectable or metastatic urothelial carcinoma who progressed on or after platinum-based therapy, in combination with docetaxel	Intravenous	http://lillyoncologypipeline.com/molecule/vegfr-receptor-2-antagonist/trials
Stivarga	regorafenib	Bayer	Previously untreated patients with metastatic or unresectable renal cell carcinoma	Oral	http://pharma.bayer.com/en/innovation-partnering/clinical-trials/trial-finder/
	savolitinib/ volitinib	AstraZeneca	Papillary renal cell carcinoma		https://www.astrazeneca.com/our-focus-areas/oncology.html
Sutent	sunitinib	Pfizer	Renal cell carcinoma adjuvant	Oral	http://www.pfizer.com/sites/default/files/product-pipeline/PfizerPipeline_1.pdf
	TAK-228	Takeda	Renal Cancer	Oral	https://www.takedaoncology.com/content/assets/Takeda-Global-Oncology-Pipeline.pdf

Cancer Drug Pipeline Information for Patient Advocacy Groups

Please note: CCAN and CADTH do not represent or warrant that any of the drug products listed in the Cancer Drug Pipeline Information for Patient Advocacy Groups will be submitted to the pCODR program. The use of this information is solely intended for informational purposes to assist patient advocacy groups to be more informed about the anticipated cancer drug products or indications that are listed in the pipeline. Please be advised that the information contained in this document is not a comprehensive list. Please contact info@canceraction.ca with any inquiries about the information contained in this document.

Brand Name	Generic Name	Manufacturer	Indication	Route of Administration	Information Source
Gynecological Cancer					
Tecentriq	atezolizumab	Hoffmann-La Roche	Ovarian cancer, front-line treatment		http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm
	avelumab	EMD Serono	Platinum resistant/refractory ovarian cancer	Intravenous	http://www.emdserono.com/en/research/Pipeline/research.html
	avelumab	EMD Serono	First line ovarian cancer	Intravenous	http://www.emdserono.com/en/research/Pipeline/research.html
	AZD1775	AstraZeneca	Ovarian cancer, in combination with chemotherapy		https://www.astrazeneca.com/our-focus-areas/oncology.html
Avastin	bevacizumab	Genentech	First-line metastatic ovarian cancer	Intravenous	http://www.gene.com/medical-professionals/pipeline
Avastin	bevacizumab	Hoffmann-La Roche	Relapsed platinum-sensitive ovarian cancer	Intravenous	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm
Cometriq	cabozantinib	Exelixis	Endometrial cancer	Oral	http://www.exelixis.com/sites/default/files/pdf/Cabozantinib%20Clinical%20Trials%20-%20November%202016.pdf
Cometriq	cabozantinib	Exelixis	High-grade uterine sarcoma	Oral	http://www.exelixis.com/sites/default/files/pdf/Cabozantinib%20Clinical%20Trials%20-%20November%202016.pdf
	cediranib	AstraZeneca	Recurrent platinum resistant ovarian cancer	Oral	https://www.astrazeneca.com/our-focus-areas/oncology.html
	farletuzumab	Eisai	Platinum-sensitive ovarian cancer	Intravenous	http://www.eisai.com/pdf/eir/erepo/epipeline.pdf
Masivet	masitinib	AB Science	Relapsed metastatic ovarian cancer - treatment of patients with advanced / metastatic epithelial ovarian cancer patients in second line being refractory to first line platinum treatment or in third line	Oral	Metastatic Castrate Resistant Prostate Cancer in first line - treatment of patients with metastatic Castrate Resistant Prostate Cancer in first line

Cancer Drug Pipeline Information for Patient Advocacy Groups

Please note: CCAN and CADTH do not represent or warrant that any of the drug products listed in the Cancer Drug Pipeline Information for Patient Advocacy Groups will be submitted to the pCODR program. The use of this information is solely intended for informational purposes to assist patient advocacy groups to be more informed about the anticipated cancer drug products or indications that are listed in the pipeline. Please be advised that the information contained in this document is not a comprehensive list. Please contact info@canceraction.ca with any inquiries about the information contained in this document.

Brand Name	Generic Name	Manufacturer	Indication	Route of Administration	Information Source
Zejula	niraparib	Tesaro, Inc.	Recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to platinum-based chemotherapy	Oral	https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm279174.htm
Keytruda	pembrolizumab	Merck	Ovarian Cancer	Intravenous	http://www.merck.com/research/pipeline/home.html
Keytruda	pembrolizumab	Merck	Renal cancer	Intravenous	http://www.merck.com/research/pipeline/home.html
	ralimetinib	Eli Lilly	Ovarian cancer	Oral	http://lillyoncologypipeline.com/clinical-phase/II
Rubraca	rucaparib	Clovis Oncology	Deleterious BRCA mutation (germline and/or somatic) associated advanced ovarian cancer who have been treated with two or more chemotherapies	Oral	http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm533891.htm
	TAK-228	Takeda	Endometrial Cancer	Oral	https://www.takedaoncology.com/content/assets/Takeda-Global-Oncology-Pipeline.pdf
Yondelis	trabectedin	Janssen	Relapsed ovarian cancer	Intravenous	http://files.shareholder.com/downloads/JNJ/2464592300x0x674691/1423ebb6-9534-413e-9af6-c0b1c429da15/JNJ_Pipeline.pdf
	veliparib	AbbVie	Ovarian cancer	Oral	http://www.abbvie.com/research-innovation/pipeline.html

Cancer Drug Pipeline Information for Patient Advocacy Groups

Please note: CCAN and CADTH do not represent or warrant that any of the drug products listed in the Cancer Drug Pipeline Information for Patient Advocacy Groups will be submitted to the pCODR program. The use of this information is solely intended for informational purposes to assist patient advocacy groups to be more informed about the anticipated cancer drug products or indications that are listed in the pipeline. Please be advised that the information contained in this document is not a comprehensive list. Please contact info@canceraction.ca with any inquiries about the information contained in this document.

Brand Name	Generic Name	Manufacturer	Indication	Route of Administration	Information Source
Head and Neck Cancer					
Giotrif	afatinib	Boehringer Ingelheim	Recurrent and/or metastatic head and neck squamous cell carcinoma who have progressed after platinum-based therapy	Oral	http://www.inoncology.com/trials/head_and_neck_cancer.html
	alpelisib	Novartis	Head and neck squamous cell carcinoma	Oral	https://www.novartis oncology.com/about-us/our-pipeline
	avelumab	EMD Serono	Locally advanced head and neck	Intravenous	http://www.emdserono.com/en/research/Pipeline/research.html
	avelumab	Pfizer	Squamous head and neck cancer	Intravenous	http://www.pfizer.com/sites/default/files/product-pipeline/PfizerPipeline_1.pdf
	avelumab	Pfizer	Locally Advanced Squamous Cell Carcinoma of the Head and Neck (Biologic)		http://www.pfizer.com/sites/default/files/product-pipeline/013117-Pipeline-Update.pdf
	buparlisib	Novartis	Glioblastoma multiforme	Oral	https://www.novartis oncology.com/about-us/our-pipeline
	buparlisib	Novartis	Head and neck cancer	Oral	https://www.novartis oncology.com/about-us/our-pipeline
	durvalumab	AstraZeneca	Squamous cell carcinoma of the head and neck	Intravenous	https://www.astrazeneca.com/our-focus-areas/oncology.html
	durvalumab + tremelimumab	AstraZeneca	2nd-line SCCHN	Intravenous	https://www.astrazeneca.com/our-focus-areas/oncology.html
	durvalumab + tremelimumab	AstraZeneca	1st-line SCCHN	Intravenous	https://www.astrazeneca.com/our-focus-areas/oncology.html
Nimoral	nimorazole	Azanta A/S	First-line head and neck squamous cell carcinoma, versus accelerated chemo-radiation therapy	Oral	http://www.azanta.com/pipeline.aspx

Cancer Drug Pipeline Information for Patient Advocacy Groups

Please note: CCAN and CADTH do not represent or warrant that any of the drug products listed in the Cancer Drug Pipeline Information for Patient Advocacy Groups will be submitted to the pCODR program. The use of this information is solely intended for informational purposes to assist patient advocacy groups to be more informed about the anticipated cancer drug products or indications that are listed in the pipeline. Please be advised that the information contained in this document is not a comprehensive list. Please contact info@canceraction.ca with any inquiries about the information contained in this document.

Brand Name	Generic Name	Manufacturer	Indication	Route of Administration	Information Source
Nimoral	nimorazole	Azanta A/S	First-line platinum-resistant head and neck squamous cell carcinoma, versus conventional radiation therapy	Oral	http://www.azanta.com/pipeline.aspx
Nimoral	nimorazole	Azanta A/S	Head and neck squamous cell carcinoma, second line re-irradiation, accelerated or conventional chemo-radiation therapy (CRT)	Oral	http://www.azanta.com/pipeline.aspx
Nimoral	nimorazole	Azanta A/S	Head and neck squamous cell carcinoma, first line accelerated chemo-radiation therapy (CRT)	Oral	http://www.azanta.com/pipeline.aspx
Ibrance	palbociclib	Pfizer	Squamous cell carcinoma of the head and neck	Oral	http://www.pfizer.com/sites/default/files/product-pipeline/PfizerPipeline_1.pdf
Keytruda	pembrolizumab	Merck	Nasopharyngeal cancer	Intravenous	http://www.merck.com/research/pipeline/home.html
Keytruda	pembrolizumab	Merck	Recurrent or metastatic head and neck squamous cell carcinoma with disease progression on or after platinum-containing chemotherapy	Intravenous	http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm515627.htm

Cancer Drug Pipeline Information for Patient Advocacy Groups

Please note: CCAN and CADTH do not represent or warrant that any of the drug products listed in the Cancer Drug Pipeline Information for Patient Advocacy Groups will be submitted to the pCODR program. The use of this information is solely intended for informational purposes to assist patient advocacy groups to be more informed about the anticipated cancer drug products or indications that are listed in the pipeline. Please be advised that the information contained in this document is not a comprehensive list. Please contact info@canceraction.ca with any inquiries about the information contained in this document.

Brand Name	Generic Name	Manufacturer	Indication	Route of Administration	Information Source
	Leukemia				
	acalabrutinib	AstraZeneca	First-line chronic lymphocytic leukemia	Oral	https://www.astrazeneca.com/our-focus-areas/oncology.html
	acalabrutinib	AstraZeneca	High-risk relapsed/refractory chronic lymphocytic leukemia	Oral	https://www.astrazeneca.com/our-focus-areas/oncology.html
	AG-221	Celgene	Acute myeloid leukemia		https://www.celgene.com/content/uploads/product-pipeline.pdf
	ASP2215	Astellas Pharma	Acute myeloid leukemia	Oral	https://www.astellas.com/en/ir/library/pdf/2q2017_rd_en.pdf
Vidaza	azacitidine for injection	Celgene	Post-induction acute myeloid leukemia maintenance	Intravenous	https://www.celgene.com/content/uploads/product-pipeline.pdf
Vidaza	azacitidine for injection	Celgene	Acute myeloid leukemia (20-30% blasts)	Intravenous	https://www.celgene.com/content/uploads/product-pipeline.pdf
Vidaza	azacitidine for injection	Celgene	Acute myeloid leukemia (>30% blasts)	Intravenous	https://www.celgene.com/content/uploads/product-pipeline.pdf
	BI 836826	Boehringer Ingelheim	Chronic lymphocytic leukemia		http://www.inoncology.com/trials/phaseII.html
Blinicyto	blinatumomab	Amgen	Relapsed/refractory Philadelphia chromosome-positive (Ph+) and minimal residual disease of acute lymphoblastic leukemia	Intravenous	http://www.amgenpipeline.com/pipeline/
Bosulif	bosutinib	Pfizer	Adult patients with newly diagnosed chronic myelogenous leukemia, versus imatinib	Oral	http://www.pfizer.com/sites/default/files/product-pipeline/PfizerPipeline_1.pdf
	durvalumab	Celgene	Acute myeloid leukemia (AML)	Intravenous	https://www.celgene.com/content/uploads/product-pipeline.pdf
	duvelisib	AbbVie	Chronic lymphocytic leukemia	Oral	http://www.abbvie.com/content/dam/abbviecorp/us/dektop/oncology/oncology-pipeline.jpg

Cancer Drug Pipeline Information for Patient Advocacy Groups

Please note: CCAN and CADTH do not represent or warrant that any of the drug products listed in the Cancer Drug Pipeline Information for Patient Advocacy Groups will be submitted to the pCODR program. The use of this information is solely intended for informational purposes to assist patient advocacy groups to be more informed about the anticipated cancer drug products or indications that are listed in the pipeline. Please be advised that the information contained in this document is not a comprehensive list. Please contact info@canceraction.ca with any inquiries about the information contained in this document.

Brand Name	Generic Name	Manufacturer	Indication	Route of Administration	Information Source
	entospletinib	Gilead Sciences	Acute Myeloid Leukemia	Oral	http://www.gilead.com/research/pipeline
	entospletinib	Gilead Sciences	Hematological Malignancies	Oral	http://www.gilead.com/research/pipeline
	gilteritinib	Astellas Pharma	Acute myeloid leukemia	Oral	https://www.astellas.com/en/ir/library/pdf/2q2017_rd_en.pdf
Imbruvica	ibrutinib	AbbVie	Acute myeloid leukemia (AML)	Oral	http://www.abbvie.com/research-innovation/pipeline.html
Imbruvica	ibrutinib	Janssen	Frontline chronic lymphocytic leukemia, in combination with obinutuzumab	Oral	http://files.shareholder.com/downloads/JNJ/200945477x0x674691/1423ebb6-9534-413e-9af6-c0b1c429da15/JNJ_Pipeline.pdf
Imbruvica	ibrutinib	Janssen	Frontline chronic lymphocytic leukemia (young and fit), in combination with rituximab	Oral	http://files.shareholder.com/downloads/JNJ/2464592300x0x674691/1423ebb6-9534-413e-9af6-c0b1c429da15/JNJ_Pipeline.pdf
	idasanutlin	Hoffmann-La Roche	Acute myeloid leukemia		http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm
Zydelig	Idelalisib	Gilead Sciences	Relapsed refractory chronic lymphocytic leukemia	Oral	http://www.gilead.com/research/pipeline
	inotuzumab ozogamicin	Pfizer	Acute lymphocytic leukemia	Intravenous	http://www.pfizer.com/sites/default/files/product-pipeline/PfizerPipeline_1.pdf
	isatuximab	Sanofi	Acute Lymphoblastic Leukemia	Intravenous	http://en.sanofi.com/Innovation/rd_portfolio/rd_portfolio.aspx
	LCL161	Novartis	Leukemia		https://www.novartis oncology.com/about-us/our-pipeline
	moxetumomab pasudotox	AstraZeneca	Hairy cell leukaemia	Intravenous	https://www.astrazeneca.com/our-focus-areas/oncology.html
	Moxetumomab pasudotox	AstraZeneca	Hairy cell leukemia	Intravenous	https://www.astrazeneca.com/our-focus-areas/oncology.html

Cancer Drug Pipeline Information for Patient Advocacy Groups

Please note: CCAN and CADTH do not represent or warrant that any of the drug products listed in the Cancer Drug Pipeline Information for Patient Advocacy Groups will be submitted to the pCODR program. The use of this information is solely intended for informational purposes to assist patient advocacy groups to be more informed about the anticipated cancer drug products or indications that are listed in the pipeline. Please be advised that the information contained in this document is not a comprehensive list. Please contact info@canceraction.ca with any inquiries about the information contained in this document.

Brand Name	Generic Name	Manufacturer	Indication	Route of Administration	Information Source
	Mylotarg	Pfizer	1st Line Acute Myeloid Leukemia (Biologic)		http://www.pfizer.com/sites/default/files/product-pipeline/013117-Pipeline-Update.pdf
Gazyva	obinutuzumab	Genentech	Front-line chronic lymphocytic leukemia	Intravenous	http://www.gene.com/medical-professionals/pipeline
Arzerra	ofatumumab	Novartis	For extended treatment of patients who are in complete or partial response after at least two lines of therapy for recurrent or progressive chronic lymphocytic leukemia (CLL)	Intravenous	http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm279174.htm
	pevonedistat	Takeda	High-risk myelodysplastic syndrome	Intravenous	https://www.takedaoncology.com/content/assets/Takeda-Global-Oncology-Pipeline.pdf
	polatuzumab vedotin	Hoffmann-La Roche	Hematological malignancies		http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm
Iclusig	ponatinib	Ariad Pharmaceuticals	Chronic-phase chronic myeloid leukemia (2nd line)	Oral	http://www.ariad.com/research-development/clinical-trials/
Iclusig	ponatinib	Takeda	Imatinib resistant chronic phase Chronic myelogenous leukemia (CML)	Oral	https://www.takedaoncology.com/content/assets/Takeda-Global-Oncology-Pipeline.pdf
Iclusig	ponatinib	Takeda	Second-line chronic phase Chronic myelogenous leukemia (CML)	Oral	https://www.takedaoncology.com/content/assets/Takeda-Global-Oncology-Pipeline.pdf
Iclusig	ponatinib	Takeda	Ph+Acute lymphoblastic leukemia (ALL)	Oral	https://www.takedaoncology.com/content/assets/Takeda-Global-Oncology-Pipeline.pdf
Rituxan	rituximab	Hoffmann-La Roche	Chronic lymphocytic leukemia	Subcutaneous	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm
	vadastuximab talirine	Seattle Genetics	Frontline older acute myeloid leukemia	Intravenous	http://www.seattlegenetics.com/pipeline
	vadastuximab talirine	Seattle Genetics	Relapsed acute myeloid leukemia pre/post allo-transplant	Intravenous	http://www.seattlegenetics.com/pipeline

Cancer Drug Pipeline Information for Patient Advocacy Groups

Please note: CCAN and CADTH do not represent or warrant that any of the drug products listed in the Cancer Drug Pipeline Information for Patient Advocacy Groups will be submitted to the pCODR program. The use of this information is solely intended for informational purposes to assist patient advocacy groups to be more informed about the anticipated cancer drug products or indications that are listed in the pipeline. Please be advised that the information contained in this document is not a comprehensive list. Please contact info@canceraction.ca with any inquiries about the information contained in this document.

Brand Name	Generic Name	Manufacturer	Indication	Route of Administration	Information Source
Venclexta	venetoclax	AbbVie	Chronic lymphocytic leukemia (CLL) - relapsed/refractory and first line	Oral	http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm279174
Venclexta	venetoclax	Hoffmann-La Roche	Frontline chronic lymphocytic leukemia, in combination with Gazyva	Oral	http://www.roche.com/research_and_development/ho_we_are_how_we_work/pipeline.htm
Venclexta	venetoclax	Hoffmann-La Roche	Relapsed/refractory chronic lymphocytic leukemia, in combination with rituximab	Oral	http://www.roche.com/research_and_development/ho_we_are_how_we_work/pipeline.htm
Venclexta	venetoclax	Hoffmann-La Roche	myelodysplastic syndromes, first-line treatment		http://www.roche.com/research_and_development/ho_we_are_how_we_work/pipeline.htm
Venclexta	venetoclax	Hoffmann-La Roche	Acute myelogenous leukemia, first-line treatment		http://www.roche.com/research_and_development/ho_we_are_how_we_work/pipeline.htm

Cancer Drug Pipeline Information for Patient Advocacy Groups

Please note: CCAN and CADTH do not represent or warrant that any of the drug products listed in the Cancer Drug Pipeline Information for Patient Advocacy Groups will be submitted to the pCODR program. The use of this information is solely intended for informational purposes to assist patient advocacy groups to be more informed about the anticipated cancer drug products or indications that are listed in the pipeline. Please be advised that the information contained in this document is not a comprehensive list. Please contact info@canceraction.ca with any inquiries about the information contained in this document.

Brand Name	Generic Name	Manufacturer	Indication	Route of Administration	Information Source
	Lung Cancer				
	abemaciclib	Eli Lilly	Stage IV NSCLC with a detectable KRAS mutation who have progressed after platinum-based chemotherapy	Oral	http://lillyoncologypipeline.com/molecule/cdk-4-and-cdk-6-inhibitor/trials
	abemaciclib	Eli Lilly	Squamous non-small cell lung cancer	Oral	http://lillyoncologypipeline.com/clinical-phase/II
Giotrif	afatinib	Boehringer Ingelheim	Advanced squamous cell carcinoma of the lung as second-line therapy following first-line platinum-based chemotherapy	Oral	http://www.inoncology.com/trials/lung_cancer/lux-lung8.html
Giotrif	afatinib	Boehringer Ingelheim	Non-small cell lung cancer after failure of erlotinib or gefitinib	Oral	http://www.inoncology.com/trials/lung_cancer.html
Giotrif	afatinib	Boehringer Ingelheim	Stage IIIB or IV adenocarcinoma of the lung harbouring an epidermal growth factor receptor (EGFR) activating mutation	Oral	http://www.inoncology.com/trials/lung_cancer.html
Giotrif	afatinib	Boehringer Ingelheim	First-line treatment of patients with common epidermal growth factor receptor (EGFR) mutations (del19/L858R) and advanced adenocarcinoma of the lung	Oral	http://www.inoncology.com/trials/lung_cancer.html
Giotrif	afatinib	Boehringer Ingelheim	Patients with non-small cell lung cancer (NSCLC) who had failed at least one line of chemotherapy and erlotinib or gefitinib treatment	Oral	http://www.inoncology.com/trials/lung_cancer.html
Alecensa	alectinib	Genentech	ALK+ metastatic non-small cell lung cancer	Oral	http://www.gene.com/medical-professionals/pipeline
	alpelisib	Novartis	Non-small cell lung cancer	Oral	https://www.novartisoncology.com/about-us/our-pipeline

Cancer Drug Pipeline Information for Patient Advocacy Groups

Please note: CCAN and CADTH do not represent or warrant that any of the drug products listed in the Cancer Drug Pipeline Information for Patient Advocacy Groups will be submitted to the pCODR program. The use of this information is solely intended for informational purposes to assist patient advocacy groups to be more informed about the anticipated cancer drug products or indications that are listed in the pipeline. Please be advised that the information contained in this document is not a comprehensive list. Please contact info@canceraction.ca with any inquiries about the information contained in this document.

Brand Name	Generic Name	Manufacturer	Indication	Route of Administration	Information Source
	amatumimab	Eisai	Mesothelioma	Intravenous	http://www.eisai.com/pdf/eir/erepo/epipeline.pdf
Tecentriq	atezolizumab	Hoffmann-La Roche	First-line non-squamous and squamous non-small cell lung cancer, PDL1-selected patients	Intravenous	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm
Tecentriq	atezolizumab	Hoffmann-La Roche	Second-line non-small cell lung cancer	Intravenous	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm
Tecentriq	atezolizumab	Hoffmann-La Roche	First-line non-squamous non-small cell lung cancer, in combination with chemotherapy, with or without Avastin	Intravenous	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm
Tecentriq	atezolizumab	Hoffmann-La Roche	Metastatic non-small cell lung cancer whose disease progressed during or following platinum-containing chemotherapy	Intravenous	http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm525780.htm
Tecentriq	atezolizumab	Hoffmann-La Roche	Non-small cell lung cancer, adjuvant treatment	Intravenous	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm
Tecentriq	atezolizumab	Hoffmann-La Roche	First-line squamous non-small cell lung cancer	Intravenous	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm
Tecentriq	atezolizumab	Hoffmann-La Roche	First-line non-squamous non-small cell lung cancer, in combination with chemotherapy	Intravenous	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm
Tecentriq	atezolizumab	Hoffmann-La Roche	First-line non-squamous non-small cell lung cancer, in combination with chemotherapy and pemetrexed	Intravenous	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm
Tecentriq	atezolizumab	Hoffmann-La Roche	First line extensive-stage small cell lung cancer	Intravenous	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm
	avelumab	EMD Serono	First line non-small cell lung cancer	Intravenous	http://www.emdserono.com/en/research/Pipeline/research.html Added

Cancer Drug Pipeline Information for Patient Advocacy Groups

Please note: CCAN and CADTH do not represent or warrant that any of the drug products listed in the Cancer Drug Pipeline Information for Patient Advocacy Groups will be submitted to the pCODR program. The use of this information is solely intended for informational purposes to assist patient advocacy groups to be more informed about the anticipated cancer drug products or indications that are listed in the pipeline. Please be advised that the information contained in this document is not a comprehensive list. Please contact info@canceraction.ca with any inquiries about the information contained in this document.

Brand Name	Generic Name	Manufacturer	Indication	Route of Administration	Information Source
	avelumab	EMD Serono	Second line non-small cell lung cancer	Intravenous	http://www.emdserono.com/en/research/Pipeline/research.html
Avastin	bevacizumab	Genentech	Adjuvant non-small cell lung cancer	Intravenous	http://www.gene.com/medical-professionals/pipeline
	BI 1361849	Boehringer Ingelheim	Non-small cell lung cancer		http://www.inoncology.com/trials/phaseII.html
	brigatinib	Ariad Pharmaceuticals	Locally advanced or metastatic NSCLC who test positive for the ALK oncogene and were previously treated with crizotinib	Oral	http://www.ariad.com/research-development/clinical-trials/
	brigatinib	Ariad Pharmaceuticals	First-line ALK-positive locally advanced or metastatic non-small cell lung cancer who have not previously been treated with an ALK inhibitor	Oral	http://www.ariad.com/research-development/clinical-trials/
Cometriq	cabozantinib	Exelixis	Non-small cell lung cancer: RET rearranged	Oral	http://www.exelixis.com/sites/default/files/pdf/Cabozantinib%20Clinical%20Trials%20-%20November%202016.pdf
Cometriq	cabozantinib	Exelixis	Non-small cell lung cancer: EGFR wild-type	Oral	http://www.exelixis.com/sites/default/files/pdf/Cabozantinib%20Clinical%20Trials%20-%20November%202016.pdf
Cometriq	cabozantinib	Exelixis	Non-small cell lung cancer: metastases to the brain	Oral	http://www.exelixis.com/sites/default/files/pdf/Cabozantinib%20Clinical%20Trials%20-%20November%202016.pdf
	capmatinib	Novartis	Non-small cell lung cancer	Oral	https://www.novartisoncology.com/about-us/our-pipeline
Kyprolis	carfilzomib	Amgen	Small-cell lung cancer	Intravenous	http://www.amgenpipeline.com/~media/amgen/full/www-amgenpipeline-com/charts/amgenpipelinedownload.ashx

Cancer Drug Pipeline Information for Patient Advocacy Groups

Please note: CCAN and CADTH do not represent or warrant that any of the drug products listed in the Cancer Drug Pipeline Information for Patient Advocacy Groups will be submitted to the pCODR program. The use of this information is solely intended for informational purposes to assist patient advocacy groups to be more informed about the anticipated cancer drug products or indications that are listed in the pipeline. Please be advised that the information contained in this document is not a comprehensive list. Please contact info@canceraction.ca with any inquiries about the information contained in this document.

Brand Name	Generic Name	Manufacturer	Indication	Route of Administration	Information Source
Xalkori	crizotinib	Pfizer	Treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are ROS1-positive	Oral	http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm279174.htm
Xalkori	crizotinib	Pfizer	ROS1-positive metastatic non-small cell lung cancer	Oral	http://www.pfizer.com/sites/default/files/product-pipeline/Produce_Pipeline_Update.pdf
	dacomitinib	Pfizer	First-line EGFR-mutant non-small cell lung cancer	Oral	http://www.pfizer.com/sites/default/files/product-pipeline/PfizerPipeline_1.pdf
	durvalumab	AstraZeneca	Stage III NSCLC	Intravenous	https://www.astrazeneca.com/our-focus-areas/oncology.html
	Durvalumab	AstraZeneca	1st-line NSCLC		https://www.astrazeneca.com/our-focus-areas/oncology.html
	durvalumab + tremelimumab	AstraZeneca	3rd-line NSCLC	Intravenous	https://www.astrazeneca.com/our-focus-areas/oncology.html
	durvalumab + tremelimumab	AstraZeneca	1st-line NSCLC	Intravenous	https://www.astrazeneca.com/our-focus-areas/oncology.html
	Durvalumab + tremelimumab	AstraZeneca	1st-line SCLC	Intravenous	https://www.astrazeneca.com/our-focus-areas/oncology.html
	EGF816	Novartis	Non-small cell lung cancer	Oral	https://www.novartisoncology.com/about-us/our-pipeline
	emibetuzumab	Eli Lilly	Non-small cell lung cancer	Intravenous	http://lillyoncologypipeline.com/clinical-phase/II
	lorlatinib	Pfizer	ALK non-small cell lung cancer	Oral	http://www.pfizer.com/sites/default/files/product-pipeline/PfizerPipeline_1.pdf
	LY3023414	Eli Lilly	Non-small cell lung cancer	Oral	http://lillyoncologypipeline.com/clinical-phase/II
	necitumumab	Eli Lilly	First-line stage IV squamous non-small cell lung cancer	Intravenous	http://lillyoncologypipeline.com/molecule/egfr-antibody/trials
	naquotinib (ASP82)	Astellas Pharma	Non-small cell lung cancer	Oral	https://www.astellas.com/en/ir/library/pdf/2q2017_rd_en.pdf

Cancer Drug Pipeline Information for Patient Advocacy Groups

Please note: CCAN and CADTH do not represent or warrant that any of the drug products listed in the Cancer Drug Pipeline Information for Patient Advocacy Groups will be submitted to the pCODR program. The use of this information is solely intended for informational purposes to assist patient advocacy groups to be more informed about the anticipated cancer drug products or indications that are listed in the pipeline. Please be advised that the information contained in this document is not a comprehensive list. Please contact info@canceraction.ca with any inquiries about the information contained in this document.

Brand Name	Generic Name	Manufacturer	Indication	Route of Administration	Information Source
Vargatef	nintedanib	Boehringer Ingelheim	Advanced or recurrent non-small cell lung cancer patients after failure of first-line therapy, in combination with pemetrexed	Oral	http://www.inoncology.com/trials/lung_cancer.html
Vargatef	nintedanib	Boehringer Ingelheim	Stage IIIB/IV or recurrent non-small cell lung cancer (NSCLC) after failure of first-line chemotherapy, in combination with docetaxel	Oral	http://www.inoncology.com/trials/lung_cancer.html
	oral azacitidine (CC-486)	Celgene	Advanced non-small cell lung cancer	Oral	https://www.celgene.com/content/uploads/product-pipeline.pdf
Tagrisso	osimertinib	AstraZeneca	Brain metastases in advanced EGFRm NSCLC	Oral	https://www.astrazeneca.com/our-focus-areas/oncology.html
Abraxane	paclitaxel	Celgene	Advanced non-small cell lung cancer (first-line)	Oral	https://www.celgene.com/content/uploads/product-pipeline.pdf
	prexasertib	Eli Lilly	Patients with extensive-stage disease small cell lung cancer who have either platinum-sensitive or platinum-resistant/refractory disease	Intravenous	http://lillyoncologypipeline.com/molecule/chk-1-inhibitor/trials
Cyramza	ramucirumab	Eli Lilly	Metastatic non-small cell lung cancer with disease progression on or after platinum-based chemotherapy, in combination with docetaxel	Intravenous	http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm426735.htm
Cyramza	ramucirumab	Eli Lilly	Previously untreated patients with EGFR mutation-positive metastatic non-small cell lung cancer	Intravenous	http://lillyoncologypipeline.com/molecule/vegfr-receptor-2-antagonist/trials
Cyramza	ramucirumab	Eli Lilly	Stage IV non-small cell lung cancer following disease progression after prior platinum-based chemotherapy, in combination with weekly docetaxel	Intravenous	http://lillyoncologypipeline.com/molecule/vegfr-receptor-2-antagonist/trials

Cancer Drug Pipeline Information for Patient Advocacy Groups

Please note: CCAN and CADTH do not represent or warrant that any of the drug products listed in the Cancer Drug Pipeline Information for Patient Advocacy Groups will be submitted to the pCODR program. The use of this information is solely intended for informational purposes to assist patient advocacy groups to be more informed about the anticipated cancer drug products or indications that are listed in the pipeline. Please be advised that the information contained in this document is not a comprehensive list. Please contact info@canceraction.ca with any inquiries about the information contained in this document.

Brand Name	Generic Name	Manufacturer	Indication	Route of Administration	Information Source
Rova-T	rovalpituzumab tesirine	AbbVie	Small cell lung cancer, third line	Intravenous	http://www.abbvie.com/research-innovation/pipeline.html
Rova-T	rovalpituzumab tesirine	AbbVie	Small cell lung cancer, first line	Intravenous	https://www.abbvie.com/our-science/pipeline.html
	tepotinib	EMD Serono	Non-small cell lung cancer	Oral	http://www.emdserono.com/en/research/Pipeline/research.html
	veliparib	AbbVie	Squamous non-small cell lung cancer	Oral	http://www.abbvie.com/research-innovation/pipeline.html
	veliparib	AbbVie	Non-squamous non-small cell lung cancer	Oral	http://www.abbvie.com/research-innovation/pipeline.html

Cancer Drug Pipeline Information for Patient Advocacy Groups

Please note: CCAN and CADTH do not represent or warrant that any of the drug products listed in the Cancer Drug Pipeline Information for Patient Advocacy Groups will be submitted to the pCODR program. The use of this information is solely intended for informational purposes to assist patient advocacy groups to be more informed about the anticipated cancer drug products or indications that are listed in the pipeline. Please be advised that the information contained in this document is not a comprehensive list. Please contact info@canceraction.ca with any inquiries about the information contained in this document.

Brand Name	Generic Name	Manufacturer	Indication	Route of Administration	Information Source
	Lymphoma and Myeloma				
	acalabrutinib	AstraZeneca	B-cell malignancy		https://www.astrazeneca.com/our-focus-areas/oncology.html
	avelumab	Pfizer	1st Line Merkel Cell Carcinoma	Intravenous	http://www.pfizer.com/sites/default/files/product-pipeline/013117-Pipeline-Update.pdf
Beleodaq	belinostat	Spectrum	Relapsed or refractory peripheral T-cell lymphoma	Intravenous	http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm403960.htm
	BI 836826	Boehringer Ingelheim	Non-Hodgkin lymphoma		http://www.inoncology.com/trials/phaseII.html
Adcetris	brentuximab vedotin	Takeda	Frontline HL	Intravenous	https://www.takedaoncology.com/content/assets/Takeda-Global-Oncology-Pipeline.pdf
Adcetris	brentuximab vedotin	Takeda	Frontline MTCL - Mature T-cell lymphoma	Intravenous	https://www.takedaoncology.com/content/assets/Takeda-Global-Oncology-Pipeline.pdf
Adcetris	brentuximab vedotin	Takeda	HL post Trsansplant	Intravenous	https://www.takedaoncology.com/content/assets/Takeda-Global-Oncology-Pipeline.pdf
Adcetris	brentuximab vedotin	Takeda	Relapsed CTCL	Intravenous	https://www.takedaoncology.com/content/assets/Takeda-Global-Oncology-Pipeline.pdf
Adcetris	brentuximab vedotin	Seattle Genetics	Frontline Hodgkin lymphoma, in combination with chemotherapy	Intravenous	http://www.seattlegenetics.com/pipeline
Adcetris	brentuximab vedotin	Seattle Genetics	Frontline CD30-expressing mature T-cell lymphomas, in combination with chemotherapy	Intravenous	http://www.seattlegenetics.com/pipeline
Adcetris	brentuximab vedotin	Seattle Genetics	CD30-expressing cutaneous T-cell lymphoma	Intravenous	http://www.seattlegenetics.com/pipeline
Adcetris	brentuximab vedotin	Seattle Genetics	Frontline Hodgkin lymphoma in patients 60+	Intravenous	http://www.seattlegenetics.com/pipeline
Adcetris	brentuximab Vedotin	Seattle Genetics	Relapsed CD30-expressing diffuse large B-cell lymphoma (rituximab + bendamustine +/- brentuximab vedotin)	Intravenous	http://www.seattlegenetics.com/pipeline

Cancer Drug Pipeline Information for Patient Advocacy Groups

Please note: CCAN and CADTH do not represent or warrant that any of the drug products listed in the Cancer Drug Pipeline Information for Patient Advocacy Groups will be submitted to the pCODR program. The use of this information is solely intended for informational purposes to assist patient advocacy groups to be more informed about the anticipated cancer drug products or indications that are listed in the pipeline. Please be advised that the information contained in this document is not a comprehensive list. Please contact info@canceraction.ca with any inquiries about the information contained in this document.

Brand Name	Generic Name	Manufacturer	Indication	Route of Administration	Information Source
Adcetris	brentuximab vedotin	Seattle Genetics	Second-line Hodgkin lymphoma, in combination with nivolumab	Intravenous	http://www.seattlegenetics.com/pipeline
Adcetris	brentuximab vedotin	Seattle Genetics	Relapsed non-Hodgkin lymphoma, in combination with nivolumab	Intravenous	http://www.seattlegenetics.com/pipeline
Alunbrig	brigatinib	Takeda	Follicular lymphoma ALK +NSCLC	Oral	https://www.takedaoncology.com/content/assets/Takeda-Global-Oncology-Pipeline.pdf
Kyprolis	carfilzomib	Amgen	Newly diagnosed multiple myeloma, in combination with melphalan and prednisone	Intravenous	http://www.amgenpipeline.com/pipeline/
	copanlisib	Bayer	Relapsed, indolent or aggressive non-Hodgkin's lymphomas	Oral	http://www.chronotrials.com/
	copanlisib	Bayer	Rituximab-refractory indolent non-Hodgkin's lymphoma	Oral	http://pharma.bayer.com/en/innovation-partnering/clinical-trials/trial-finder/
	copanlisib	Bayer	Relapsed indolent non-Hodgkin's lymphoma, in combination with rituximab	Oral	http://www.chronotrials.com/
	copanlisib	Bayer	Relapsed indolent non-Hodgkin's lymphoma, in combination with standard immunochemotherapy	Oral	http://www.chronotrials.com/
	copanlisib	Bayer	Diffuse large B-cell lymphoma	Oral	http://www.chronotrials.com/
	copanlisib	Bayer	Mantle cell lymphoma	Oral	http://pharma.bayer.com/en/innovation-partnering/clinical-trials/trial-finder/
Darzalex	daratumumab	Janssen	Frontline multiple myeloma transplant-ineligible patients, in combination with bortezomib, melphalan and prednisone	Intravenous	http://files.shareholder.com/downloads/JNJ/200945477x0x674691/1423ebb6-9534-413e-9af6-c0b1c429da15/JNJ_Pipeline.pdf
Darzalex	daratumumab	Janssen	Frontline multiple myeloma transplant-ineligible patients, in combination with lenalidomide and low-dose dexamethasone	Intravenous	http://files.shareholder.com/downloads/JNJ/200945477x0x674691/1423ebb6-9534-413e-9af6-c0b1c429da15/JNJ_Pipeline.pdf

Cancer Drug Pipeline Information for Patient Advocacy Groups

Please note: CCAN and CADTH do not represent or warrant that any of the drug products listed in the Cancer Drug Pipeline Information for Patient Advocacy Groups will be submitted to the pCODR program. The use of this information is solely intended for informational purposes to assist patient advocacy groups to be more informed about the anticipated cancer drug products or indications that are listed in the pipeline. Please be advised that the information contained in this document is not a comprehensive list. Please contact info@canceraction.ca with any inquiries about the information contained in this document.

Brand Name	Generic Name	Manufacturer	Indication	Route of Administration	Information Source
Darzalex	daratumumab	Janssen	Frontline multiple myeloma transplant-eligible patients, in combination with velcade, thalidomide and dexamethasone	Intravenous	http://files.shareholder.com/downloads/JNJ/200945477x0x674691/1423ebb6-9534-413e-9af6-c0b1c429da15/JNJ_Pipeline.pdf
Darzalex	daratumumab	Janssen	Double refractory multiple myeloma	Intravenous	http://files.shareholder.com/downloads/JNJ/2464592300x0x674691/1423ebb6-9534-413e-9af6-c0b1c429da15/JNJ_Pipeline.pdf
	denintuzumab mafodotin	Seattle Genetics	Relapsed diffuse large B-cell lymphoma (rituximab + chemotherapy +/- SGN-CD19A)	Intravenous	http://www.seattlegenetics.com/pipeline
	denintuzumab mafodotin	Seattle Genetics	Frontline diffuse large B-cell lymphoma, in combination with chemotherapy (planned)	Intravenous	http://www.seattlegenetics.com/pipeline
Empliciti	elotuzumab	AbbVie	Multiple myeloma treatment naïve	Intravenous	http://www.abbvie.com/research-innovation/pipeline.html
Empliciti	elotuzumab	AbbVie	Multiple myeloma, previously treated	Intravenous	http://www.abbvie.com/research-innovation/pipeline.html
Imbruvica	ibrutinib	AbbVie	Multiple myeloma	Oral	https://www.abbvie.com/our-science/pipeline.html
Imbruvica	ibrutinib	AbbVie	Marginal zone lymphoma (MZL), relapsed/refractory	Oral	https://www.abbvie.com/our-science/pipeline.html
Imbruvica	ibrutinib	AbbVie	Diffuse large B-cell lymphoma	Oral	https://www.abbvie.com/our-science/pipeline.html
Imbruvica	ibrutinib	AbbVie	Follicular lymphoma	Oral	https://www.abbvie.com/our-science/pipeline.html
Imbruvica	ibrutinib	Janssen	Patients with mantle cell lymphoma who have received at least one prior therapy	Oral	http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm374857.htm

Cancer Drug Pipeline Information for Patient Advocacy Groups

Please note: CCAN and CADTH do not represent or warrant that any of the drug products listed in the Cancer Drug Pipeline Information for Patient Advocacy Groups will be submitted to the pCODR program. The use of this information is solely intended for informational purposes to assist patient advocacy groups to be more informed about the anticipated cancer drug products or indications that are listed in the pipeline. Please be advised that the information contained in this document is not a comprehensive list. Please contact info@canceraction.ca with any inquiries about the information contained in this document.

Brand Name	Generic Name	Manufacturer	Indication	Route of Administration	Information Source
Imbruvica	ibrutinib	Janssen	Treatment naive patients with mantle cell lymphoma, in combination with Bendamustine and Rituximab	Oral	http://files.shareholder.com/downloads/JNJ/2464592300x0x674691/1423ebb6-9534-413e-9af6-c0b1c429da15/JNJ_Pipeline.pdf
Imbruvica	ibrutinib	Janssen	Relapsed/refractory indolent non-Hodgkin's lymphoma, in combination with bendamustine and rituximab or R-CHOP	Oral	http://files.shareholder.com/downloads/JNJ/2464592300x0x674691/1423ebb6-9534-413e-9af6-c0b1c429da15/JNJ_Pipeline.pdf
Imbruvica	ibrutinib	Janssen	Newly diagnosed non-germinal centre B-cell subtype of diffuse large B-cell lymphoma, in combination with R-CHOP	Oral	http://files.shareholder.com/downloads/JNJ/2464592300x0x674691/1423ebb6-9534-413e-9af6-c0b1c429da15/JNJ_Pipeline.pdf
Imbruvica	ibrutinib	Janssen	Marginal zone lymphoma in patients who have received at least one prior therapy	Oral	http://files.shareholder.com/downloads/JNJ/2464592300x0x674691/1423ebb6-9534-413e-9af6-c0b1c429da15/JNJ_Pipeline.pdf
Imbruvica	ibrutinib	Janssen	Marginal zone lymphoma in patients who have received at least one prior therapy	Oral	http://files.shareholder.com/downloads/JNJ/2464592300x0x674691/1423ebb6-9534-413e-9af6-c0b1c429da15/JNJ_Pipeline.pdf
	isatuximab	Sanofi	Relapsed refractory multiple myeloma	Intravenous	http://en.sanofi.com/rd/rd_portfolio/rd_portfolio.aspx
Ninlaro	ixazomib	Takeda	Relapsed refractory multiple myeloma amyloidosis	Oral	https://www.takedaoncology.com/content/assets/Takeda-Global-Oncology-Pipeline.pdf
Ninlaro	ixazomib	Takeda	Multiple myeloma maintenance non SCT	Oral	https://www.takedaoncology.com/content/assets/Takeda-Global-Oncology-Pipeline.pdf
Ninlaro	ixazomib	Takeda	Multiple myeloma maintenance post SCT	Oral	https://www.takedaoncology.com/content/assets/Takeda-Global-Oncology-Pipeline.pdf
Ninlaro	ixazomib	Takeda	Newly diagnosed multiple myeloma	Oral	https://www.takedaoncology.com/content/assets/Takeda-Global-Oncology-Pipeline.pdf

Cancer Drug Pipeline Information for Patient Advocacy Groups

Please note: CCAN and CADTH do not represent or warrant that any of the drug products listed in the Cancer Drug Pipeline Information for Patient Advocacy Groups will be submitted to the pCODR program. The use of this information is solely intended for informational purposes to assist patient advocacy groups to be more informed about the anticipated cancer drug products or indications that are listed in the pipeline. Please be advised that the information contained in this document is not a comprehensive list. Please contact info@canceraction.ca with any inquiries about the information contained in this document.

Brand Name	Generic Name	Manufacturer	Indication	Route of Administration	Information Source
	LCL161	Novartis	Multiple myeloma		https://www.novartis oncology.com/about-us/our-pipeline
Revlimid	lenalidomide	Celgene	First-line diffuse large B-cell lymphoma (ABC-subtype)	Oral	http://www.celgene.com/content/uploads/product-pipeline.pdf
Revlimid	lenalidomide	Celgene	Relapsed/refractory indolent lymphoma	Oral	https://www.celgene.com/content/uploads/product-pipeline.pdf
Revlimid	lenalidomide	Celgene	First-line follicular lymphoma	Oral	https://www.celgene.com/content/uploads/product-pipeline.pdf
Revlimid	lenalidomide	Celgene	Mantle cell lymphoma whose disease has relapsed or progressed after two prior therapies, one of which included bortezomid	Oral	http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm355438.htm
Revlimid	lenalidomide	Celgene	Relapsed/refractory multiple myeloma	Oral	https://www.celgene.com/content/uploads/product-pipeline.pdf
Revlimid	lenalidomide	Celgene	Maintenance therapy for patients with multiple myeloma following autologous stem cell transplant	Oral	https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm542791.htm
Masivet	masitinib	AB Science	Relapsed peripheral T-cell lymphoma - treatment of patients with relapsed or refractory peripheral T-cell lymphoma	Oral	Metastatic Castrate Resistant Prostate Cancer in first line - treatment of patients with metastatic Castrate Resistant Prostate Cancer in first line
Opdivo	nivolumab	Bristol-Myers Squibb	For patients with classical Hodgkin lymphoma (cHL) that has relapsed or progressed after autologous hematopoietic stem cell transplantation (HSCT) and post-transplantation brentuximab vedotin (Adcetris)	Intravenous	http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm501412.htm
Gazyva	obinutuzumab	Genentech	Diffuse large B-cell lymphoma	Intravenous	http://www.gene.com/medical-professionals/pipeline

Cancer Drug Pipeline Information for Patient Advocacy Groups

Please note: CCAN and CADTH do not represent or warrant that any of the drug products listed in the Cancer Drug Pipeline Information for Patient Advocacy Groups will be submitted to the pCODR program. The use of this information is solely intended for informational purposes to assist patient advocacy groups to be more informed about the anticipated cancer drug products or indications that are listed in the pipeline. Please be advised that the information contained in this document is not a comprehensive list. Please contact info@canceraction.ca with any inquiries about the information contained in this document.

Brand Name	Generic Name	Manufacturer	Indication	Route of Administration	Information Source
Gazyva	obinutuzumab	Genentech	Refractory indolent non-Hodgkin's lymphoma	Intravenous	http://www.gene.com/medical-professionals/pipeline
Gazyva	obinutuzumab	Hoffmann-La Roche	Front-line indolent non-Hodgkin's lymphoma	Intravenous	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm
Farydak	panobinostat	Novartis	Multiple myeloma, in combination with bortezomib and dexamethasone, for patients who have received at least two prior regimens including bortezomib and an immunomodulatory agent	Oral	http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm435339.htm
Keytruda	pembrolizumab	Merck	Multiple myeloma	Intravenous	http://www.merck.com/research/pipeline/home.html
Keytruda	pembrolizumab	Merck	Primary mediastinal primary B-cell lymphoma	Intravenous	http://www.merck.com/research/pipeline/home.html
	polatuzumab vedotin	Genentech	Non-Hodgkin's lymphoma and diffuse large B-cell lymphoma	Intravenous	http://www.gene.com/medical-professionals/pipeline
Rituxan Hycelea	rituximab and hyaluronidase human	Genentech	follicular lymphoma, diffuse large B-cell lymphoma, and chronic lymphocytic leukemia	Intravenous	https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm564235.htm
Istodax	romidepsin	Celgene	First-line peripheral T-cell lymphoma	Intravenous	https://www.celgene.com/content/uploads/product-pipeline.pdf
Istodax	romidepsin	Celgene	Cutaneous T-cell lymphoma	Intravenous	https://www.celgene.com/content/uploads/product-pipeline.pdf
Thalomid	thalidomide	Celgene	Newly diagnosed multiple myeloma	Oral	https://www.celgene.com/content/uploads/product-pipeline.pdf
	Tirabrutinib	Gilead Sciences	B-cell malignancies	Oral	http://www.gilead.com/research/pipeline
Venclexta	venetoclax	AbbVie	Non-hodgkin lymphoma	Oral	http://www.abbvie.com/research-innovation/pipeline.html

Cancer Drug Pipeline Information for Patient Advocacy Groups

Please note: CCAN and CADTH do not represent or warrant that any of the drug products listed in the Cancer Drug Pipeline Information for Patient Advocacy Groups will be submitted to the pCODR program. The use of this information is solely intended for informational purposes to assist patient advocacy groups to be more informed about the anticipated cancer drug products or indications that are listed in the pipeline. Please be advised that the information contained in this document is not a comprehensive list. Please contact info@canceraction.ca with any inquiries about the information contained in this document.

Brand Name	Generic Name	Manufacturer	Indication	Route of Administration	Information Source
Venclexta	venetoclax	Hoffmann-La Roche	Front-line diffuse large B-cell lymphoma	Oral	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm
Venclexta	venetoclax	Hoffmann-La Roche	Relapsed/refractory follicular lymphoma, in combination with rituximab	Oral	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm
Venclexta	venetoclax	Hoffmann-La Roche	Relapsed or refractory multiple myeloma	Oral	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm

Cancer Drug Pipeline Information for Patient Advocacy Groups

Please note: CCAN and CADTH do not represent or warrant that any of the drug products listed in the Cancer Drug Pipeline Information for Patient Advocacy Groups will be submitted to the pCODR program. The use of this information is solely intended for informational purposes to assist patient advocacy groups to be more informed about the anticipated cancer drug products or indications that are listed in the pipeline. Please be advised that the information contained in this document is not a comprehensive list. Please contact info@canceraction.ca with any inquiries about the information contained in this document.

Brand Name	Generic Name	Manufacturer	Indication	Route of Administration	Information Source
	Melanoma				
	avelumab	Pfizer	Melanoma	Intravenous	http://www.pfizer.com/sites/default/files/product-pipeline/PfizerPipeline_1.pdf
	binimetinib	Array BioPharma	BRAF-mutant melanoma	Oral	http://www.arraybiopharma.com/product-pipeline/binimetinib/
Cotellic + Tecentriq + Zelboraf	cobimetinib + atezolizumab + vemurafenib	Hoffmann-La Roche	BRAFv600 mutation-positive advanced melanoma, first-line treatment		http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm
	encorafenib	Array BioPharma	BRAF V600 mutant melanoma	Oral	http://www.arraybiopharma.com/product-pipeline/encorafenib-lqx818/
Masivet	masitinib	AB Science	Metastatic melanoma with JM mutation of c-KIT	Oral	http://www.ab-science.com/en/human-medicine/masitinib-in-oncology
	MORAb-004	Eisai	Melanoma	Intravenous	http://www.eisai.com/pdf/eir/erepo/epipeline.pdf
Imlygic	talimogene laherparepvec	Amgen	Mid to late-stage metastatic melanoma in combination with Keytruda	Subcutaneous	http://www.amgenpipeline.com/pipeline/
Zelboraf	vemurafenib	Hoffmann-La Roche	Adjuvant melanoma, BRAF mutation positive	Oral	http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm

Cancer Drug Pipeline Information for Patient Advocacy Groups

Please note: CCAN and CADTH do not represent or warrant that any of the drug products listed in the Cancer Drug Pipeline Information for Patient Advocacy Groups will be submitted to the pCODR program. The use of this information is solely intended for informational purposes to assist patient advocacy groups to be more informed about the anticipated cancer drug products or indications that are listed in the pipeline. Please be advised that the information contained in this document is not a comprehensive list. Please contact info@canceraction.ca with any inquiries about the information contained in this document.

Brand Name	Generic Name	Manufacturer	Indication	Route of Administration	Information Source
Neurological Cancer					
	abemaciclib	Eli Lilly	Patients with brain metastases secondary to hormone-receptor-positive breast cancer, non-small cell lung cancer, or melanoma	Oral	http://lillyoncologypipeline.com/molecule/cdk-4-and-cdk-6-inhibitor/trials
	ABT-414	AbbVie	Glioblastoma Multiforme		http://www.abbvie.com/research-innovation/pipeline.html
Avastin	bevacizumab	Genentech	First-line glioblastoma multiforme	Intravenous	http://www.gene.com/medical-professionals/pipeline
Unituxin	dinutuximab	United Therapeutics	High-risk neuroblastoma in combination with GM-CSF, IL-2 and 13-cis-retinoic acid, for pediatric patients who have achieved at least a partial response to prior first-line multiagent, multimodality therapy	Intravenous	http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm437480.htm

Sarcoma					
Cometriq	cabozantinib	Exelixis	Advanced soft tissue carcinoma	Oral	http://www.exelixis.com/sites/default/files/pdf/Cabozantinib%20Clinical%20Trials%20-%20November%202016.pdf
Halaven	eribulin	Eisai	Advanced soft tissue sarcoma	Intravenous	http://www.eisai.com/pdf/eir/erepo/epipeline.pdf
	olaratumab	Eli Lilly	Soft tissue sarcoma not amenable to curative treatment with radiotherapy or surgery and with a histologic subtype for which an anthracycline-containing regimen is appropriate	Intravenous	http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm526087.htm

Cancer Drug Pipeline Information for Patient Advocacy Groups

Please note: CCAN and CADTH do not represent or warrant that any of the drug products listed in the Cancer Drug Pipeline Information for Patient Advocacy Groups will be submitted to the pCODR program. The use of this information is solely intended for informational purposes to assist patient advocacy groups to be more informed about the anticipated cancer drug products or indications that are listed in the pipeline. Please be advised that the information contained in this document is not a comprehensive list. Please contact info@canceraction.ca with any inquiries about the information contained in this document.

Brand Name	Generic Name	Manufacturer	Indication	Route of Administration	Information Source
	Other				
	avelumab	EMD Serono	Merkel cell carcinoma	Intravenous	http://www.emdserono.com/en/research/Pipeline/research.html
Vidaza	azacitidine for injection	Celgene	Myelodysplastic syndromes	Intravenous	https://www.celgene.com/content/uploads/product-pipeline.pdf
Xgeva	denosumab	Amgen	Adults and skeletally-mature adolescents with giant cell tumor of bone that is unresectable or where surgical resection is likely to result in severe morbidity	Subcutaneous	http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm356667.htm
Revlimid	lenalidomide	Celgene	Myelodysplastic syndrome - deletion 5q	Oral	http://www.celgene.com/content/uploads/product-pipeline.pdf
	luspatercept	Celgene	Myelodysplastic syndrome	Subcutaneous	https://www.celgene.com/content/uploads/product-pipeline.pdf
	oral azacitidine (CC-486)	Celgene	Lower-risk myelodysplastic syndrome	Oral	https://www.celgene.com/content/uploads/product-pipeline.pdf
	oral azacitidine (CC-486)	Celgene	Myelodysplastic syndrome - post hypomethylating agent failure	Oral	https://www.celgene.com/content/uploads/product-pipeline.pdf
	SAR439684	Sanofi	Advanced cutaneous squamous cell carcinoma		http://en.sanofi.com/rd/rd_portfolio/rd_portfolio.aspx
Odomzo	sonidegib	Novartis	For the treatment of patients with locally advanced basal cell carcinoma (BCC) that has recurred following surgery or radiation therapy, or those who are not candidates for surgery or radiation therapy.	Oral	http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm455865.htm
	durvalumab	Celgene	Myelodysplastic syndrome	Intravenous	https://www.celgene.com/content/uploads/product-pipeline.pdf
	imetelstat	Janssen	Relapsed/refractory myelofibrosis	Intravenous	http://files.shareholder.com/downloads/JNJ/1513548902x0x674691/1423ebb6-9534-413e-9af6-c0b1c429da15/JNJ_Pipeline.pdf

Cancer Drug Pipeline Information for Patient Advocacy Groups

Please note: CCAN and CADTH do not represent or warrant that any of the drug products listed in the Cancer Drug Pipeline Information for Patient Advocacy Groups will be submitted to the pCODR program. The use of this information is solely intended for informational purposes to assist patient advocacy groups to be more informed about the anticipated cancer drug products or indications that are listed in the pipeline. Please be advised that the information contained in this document is not a comprehensive list. Please contact info@canceraction.ca with any inquiries about the information contained in this document.

Brand Name	Generic Name	Manufacturer	Indication	Route of Administration	Information Source
Vargatef	nintedanib	Boehringer Ingelheim	Unresectable malignant pleural mesothelioma, in combination with pemetrexed/cisplatin	Oral	http://www.inoncology.com/products/nintedanib-vargatef.html
	SAR439684	Sanofi	PD-1 inhibitor Advanced CSCC (Skin cancer)		http://en.sanofi.com/Innovation/rd_portfolio/rd_portfolio.aspx
Odomzo	sonidegib	Novartis	locally advanced basal cell carcinoma	Oral	http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm455865.htm
	vadastuximab talirine	Seattle Genetics	Frontline myelodysplastic syndrome, in combination with hypomethylating agents	Intravenous	http://www.seattlegenetics.com/pipeline